|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||356.40 - 362.75|
|52-week range||300.45 - 433.65|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||36.08|
|Earnings date||09 Feb 2023|
|Forward dividend & yield||4.80 (1.33%)|
|Ex-dividend date||27 Apr 2022|
|1y target est||368.46|
L'Oréal (ENXT: OR) (OTC: LRLCY) might seem like a great stock to buy as inflation, rising interest rates, and other macro headwinds rattle the broader markets. The French cosmetics giant -- which also owns Lancôme, Maybelline, NYX Cosmetics, and Garnier -- mainly targets higher-income consumers who are better insulated from those economic shockwaves.
L'Oreal SA on Tuesday failed to persuade a U.S. judge in Manhattan to dismiss a proposed class action lawsuit accusing the company of defrauding shoppers by suggesting that two topical collagen products help smooth wrinkles. The plaintiffs Rocio Lopez and Rachel Lumbra sued in August 2021, claiming that L'Oreal violated New York and California consumer protection laws by deceiving them into overpaying for its Collagen Moisture Filler Day/Night Cream and its Fragrance-Free Collagen Moisture Filler Daily Moisturizer. According to the complaint, topically applied collagen is too large to be absorbed by the epidermis, the uppermost layer of skin, making the products incapable of helping "smooth wrinkles" and "restore skin's cushion" as the labels suggest.